Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply
Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.
Pharma & Biotech
Pharma & Biotech
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
Pharma & Biotech
What Orion Corporation’s FDA orphan designation for ODM-212 means for mesothelioma treatment innovation
Discover how Orion Corporation’s ODM-212 orphan drug status could reshape mesothelioma treatment and drive innovation in Hippo pathway targeting.